Development of an efficient cell-based assay system for monitoring hepatitis C virus genotype 4a NS3/4A protease activity.

Indian J Pathol Microbiol 2019 Jul-Sep;62(3):391-398

Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.

Background: Hepatitis C virus (HCV) represents a serious worldwide healthcare problem. No protective vaccines against HCV have been developed yet due to the fact that HCV is rapidly mutable, allowing the virus to escape from the neutralizing antibodies. Understanding of HCV was initially hampered by the inability to achieve viral replication in cell culture. Given its essential roles in viral polyprotein processing and immune evasion, HCV NS3/4A protease is a prime target for antiviral chemotherapy. We aimed to establish in vivo cell-based assay system for monitoring the activity of NS3/4A protease from HCV genotype 4a, the predominant genotype in Egypt, and the Middle East. Furthermore, the developed system was used to evaluate the inhibitory potency of a series of computer-designed chemically-synthesized compounds against NS3/4A protease from HCV genotype 4a.

Materials And Methods: Native as well as mutant cleavage sites to NS3/4A protease were cloned in frame into β-galactosidase gene of TA cloning vector. The target specificity of HCV NS3/4A was evaluated by coexpression of β-galactosidase containing the protease cleavage site with NS3/4A protease construct in bacterial cells. The activity of β-galactosidase was colorimetrically estimated in the cell lysate using orthonitro phenyl β-D-galactopyanoside (ONPG) as a substrate.

Results And Conclusions: We successfully developed an efficient cell-based system based on the blue/white selection of bacterial cells that are able to express functional/nonfunctional β-galactosidase enzyme.

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_774_18DOI Listing
December 2019
Save 15% Survey

Similar Publications

Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.

Curr Pharm Des 2018 ;24(37):4484-4491

Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo, Egypt.

Background: Hepatitis C virus (HCV) infection poses a considerable threat to the public health. The current standard of care treatment with pegylated interferon-alpha in combination with ribavirin (PEG-IFN- α+RBV) is associated with significant side effects, poorly tolerated, and provides limited efficacy. The development of direct-acting antiviral agents (DAAs) targeting key viral enzymes essential for viral replication represents a significant milestone in the treatment of chronic HCV infection. Read More

View Article and Full-Text PDF
November 2019

Development of a cell-based assay for monitoring specific hepatitis C virus NS3/4A protease activity in mammalian cells.

Anal Biochem 2003 May;316(2):162-70

Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei 115, Taiwan, Republic of China.

The hepatitis C virus (HCV) contains a positive-sense RNA genome that encodes a unique polyprotein precursor, which must be processed by proteases to enable viral maturation. Virally encoded NS3/4A protease has thus become an attractive target for the development of antiviral drugs. To establish an assay system for monitoring NS3/4A protease activity in mammalian cells, this study describes a substrate vector, pEG(Delta4AB)SEAP, in which enhanced green fluorescent protein (EGFP) was fused to secreted alkaline phosphatase (SEAP) through the NS3/4A protease decapeptide recognition sequence, Delta4AB, which spans the NS4A and NS4B junction region. Read More

View Article and Full-Text PDF
May 2003

Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate.

J Virol Methods 2015 Dec 21;225:76-86. Epub 2015 Sep 21.

Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404, USA.

The hepatitis C virus (HCV) NS3/4A protease is a key target of efforts to develop direct-acting antiviral inhibitors for treatment of chronic HCV infection. In vitro analyses of the effects of NS3/4A mutations and polymorphisms on protease inhibitor (PI) susceptibility are essential to nonclinical and clinical compound characterization, but can be hampered by time and technical limitations of current in vitro methods using replicon or purified protein systems. We have developed a fast and simple method utilizing full-length NS3/4A protease inducibly expressed in Escherichia coli cells. Read More

View Article and Full-Text PDF
December 2015

Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.

Acta Virol 2008 ;52(3):133-41

Department of Microbiology, Fourth Medical Military University, and Department of Blood Transfusion, Xijing Hospital, Shaanzi, PR China.

Hepatitis C virus (HCV) NS3/4A (non-structural 3 and 4 B) protease plays a key role in the processing of polyprotein precursor and it becomes an attractive target for antiviral drug discovery. We developed a cell-based assay for monitoring of the NS3/4A protease activity in mammalian cells that is an important step in screening of specific drugs against the protease. The recombinant caspase 3 (rCasp3) was used as the specific substrate for NS3/4A protease. Read More

View Article and Full-Text PDF
December 2008